<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04506983</url>
  </required_header>
  <id_info>
    <org_study_id>HXYT-009</org_study_id>
    <nct_id>NCT04506983</nct_id>
  </id_info>
  <brief_title>GPC3-CAR-T Cells for the Hepatocellular Carcinoma</brief_title>
  <official_title>The Phase I Efficacy and Safety Clinical Study of GPC3-CAR-T Cells in Hepatocellular Carcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tsinghua Chang Gung Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China Immunotech (Beijing) Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Tsinghua Chang Gung Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, single arm, open-label, phase I study to evaluate the safety and&#xD;
      efficacy of GPC3-CAR-T cells in patients with hepatocellular carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GPC3-CAR-T cells is a novel CAR-T cells which designed for the cell membrane protein&#xD;
      Glypican-3. Patients with hepatocellular carcinoma will be enrolled, and GPC3-CAR-T cells&#xD;
      will be intravenously infused with a escalated dose of 1×106, 3×106, 10×106 GPC3-CAR-T cells.&#xD;
      Tumor markers and GPC3-CAR-T cell proliferation will be monitored in the scheduled time (day&#xD;
      0, day 4, day 7, day 10, day 14, day 28). The aim of this clinical trial is to evaluate the&#xD;
      safety and efficacy of GPC3-CAR-T cells therapy in patients with hepatocellular carcinoma.&#xD;
      The primary endpoint is the safety of CAR-T cells including the effect ratio of CRS and&#xD;
      ICANS, ORR. The secondary endpoint is the CAR-T ratio and CAR gene copied number in PB, PFS,&#xD;
      OS and DOR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 10, 2021</start_date>
  <completion_date type="Anticipated">October 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of adverse events</measure>
    <time_frame>12months</time_frame>
    <description>Percentage of participants with adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Remission Rate(ORR)</measure>
    <time_frame>12months</time_frame>
    <description>The percentage of participants who achieved complete remission (CR) and partial remission over all participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proliferation ratio of CAR-T cells</measure>
    <time_frame>12months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>GPC3-CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with hepatocellular carcinoma will be enrolled, and GPC3-CAR-T cells will be intravenously infused with a escalated dose of 1×106 /3×106/10×106GPC3-CAR-T cells. Tumor markers and GPC3-CAR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 21, day 28).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GPC3-CAR-T cells</intervention_name>
    <description>Patients with hepatocellular carcinoma will be enrolled, and GPC3-CAR-T cells will be intravenously infused with a escalated dose of 1×106 /3×106/10×106GPC3-CAR-T cells.</description>
    <arm_group_label>GPC3-CAR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≧18years, gender unlimited.&#xD;
&#xD;
          2. Failure or intolerance after at least first-line treatment.&#xD;
&#xD;
          3. GPC3 positive(IHC)&#xD;
&#xD;
          4. Patients must have at least one target lesion available for evaluation.&#xD;
&#xD;
          5. BCLC B or C.&#xD;
&#xD;
          6. Child-Pugh grade A or B&#xD;
&#xD;
          7. ECOG is 0 or 1 (one week before enrollment.)&#xD;
&#xD;
          8. Estimated life expectancy ≥ 3 months.&#xD;
&#xD;
          9. Functioning of major organs are normal.&#xD;
&#xD;
         10. Women of childbearing age (15-49 years old) must receive a pregnancy test within 7&#xD;
             days prior to initiation of treatment and the results are negative; male and female&#xD;
             patients with fertility must use an effective contraceptive to ensure 3 months after&#xD;
             discontinuation of treatment during the study period not pregnant inside.&#xD;
&#xD;
         11. Patients who voluntarily sign informed consent and are willing to comply with&#xD;
             treatment plans, visit arrangements, laboratory tests and other research procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. There are uncontrollable active infections that need systemic treatment.&#xD;
&#xD;
          2. HIV antibody is positive or syphilis antibody is positive.&#xD;
&#xD;
          3. Pregnant or lactating women.&#xD;
&#xD;
          4. hepatic encephalopathy.&#xD;
&#xD;
          5. patients with organ failure:&#xD;
&#xD;
               -  Heart: NYHA heart function grade IV;&#xD;
&#xD;
               -  Liver: Grade C that achieves Child-Turcotte liver function grading;&#xD;
&#xD;
               -  Kidney: kidney failure and uremia;&#xD;
&#xD;
               -  Lung: symptoms of respiratory failure;&#xD;
&#xD;
               -  Brain: a person with a disability.&#xD;
&#xD;
          6. It is undergoing systemic hormones therapy.&#xD;
&#xD;
          7. Impact results show that over 50% of the liver is occupied by tumor .&#xD;
&#xD;
          8. Patients who are still in the observation stage of other antitumor drugs 30 days&#xD;
             before blood collection.&#xD;
&#xD;
          9. Patients were received other gene therapy products, or are participating in other&#xD;
             clinical trials within 4 weeks prior to cell infusion.&#xD;
&#xD;
         10. Abnormal thyroid function ≧Level 3.&#xD;
&#xD;
         11. Active autoimmune diseases require systemic treatment during the first two years of&#xD;
             screening.&#xD;
&#xD;
         12. Patients have mental illness or history of drug abuse.&#xD;
&#xD;
         13. Patients are participating in other clinical studies.&#xD;
&#xD;
         14. The researchers found that it was unsuitable for the recipients to be enrolled.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gong Li, M.A.</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Tsinghua Changgeng Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gong Li, M.A.</last_name>
    <phone>13366061906</phone>
    <email>dr_gongli@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tsinghua Changgung Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Gong Li, M.A.</last_name>
      <phone>13366061906</phone>
      <email>dr_gongli@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

